Observational Study of the Impact on Quality-of-life of a Switch From a Virologically Effective Regimen to a Regimen Containing a Non-Nucleoside Reverse Transcriptase Inhibitor (QUALVI) Nevirapine (Viramune(R)) Clinical Phase IV

Trial Profile

Observational Study of the Impact on Quality-of-life of a Switch From a Virologically Effective Regimen to a Regimen Containing a Non-Nucleoside Reverse Transcriptase Inhibitor (QUALVI) Nevirapine (Viramune(R)) Clinical Phase IV

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2014

At a glance

  • Drugs Nevirapine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms QUALVI
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top